A randomized, open-label Phase III study to assess efficacy and safety of bevacizumab in combination with capecitabine as first line treatment for elderly patients with metastatic colorectal cancer

To determine the efficacy of bevacizumab in combination with capecitabine, based on progression free survival (PFS).